Zhejiang Huahai Pharmaceutical Co Ltd (600521) - Net Assets

Latest as of September 2025: CN¥9.60 Billion CNY

Based on the latest financial reports, Zhejiang Huahai Pharmaceutical Co Ltd (600521) has net assets worth CN¥9.60 Billion CNY as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥21.15 Billion) and total liabilities (CN¥11.55 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥9.60 Billion
% of Total Assets 45.38%
Annual Growth Rate 22.8%
5-Year Change 34.14%
10-Year Change 142.45%
Growth Volatility 147.88

Zhejiang Huahai Pharmaceutical Co Ltd - Net Assets Trend (2000–2024)

This chart illustrates how Zhejiang Huahai Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Zhejiang Huahai Pharmaceutical Co Ltd (2000–2024)

The table below shows the annual net assets of Zhejiang Huahai Pharmaceutical Co Ltd from 2000 to 2024.

Year Net Assets Change
2024-12-31 CN¥9.02 Billion +9.32%
2023-12-31 CN¥8.25 Billion +6.53%
2022-12-31 CN¥7.75 Billion +14.30%
2021-12-31 CN¥6.78 Billion +0.78%
2020-12-31 CN¥6.72 Billion +16.36%
2019-12-31 CN¥5.78 Billion +37.37%
2018-12-31 CN¥4.21 Billion -16.78%
2017-12-31 CN¥5.05 Billion +10.42%
2016-12-31 CN¥4.58 Billion +23.05%
2015-12-31 CN¥3.72 Billion +13.91%
2014-12-31 CN¥3.27 Billion +8.17%
2013-12-31 CN¥3.02 Billion +54.91%
2012-12-31 CN¥1.95 Billion +27.42%
2011-12-31 CN¥1.53 Billion +16.02%
2010-12-31 CN¥1.32 Billion +8.75%
2009-12-31 CN¥1.21 Billion +9.90%
2008-12-31 CN¥1.10 Billion +13.07%
2007-12-31 CN¥975.52 Million +11.44%
2006-12-31 CN¥875.40 Million +9.11%
2005-12-31 CN¥802.34 Million +2.14%
2004-12-31 CN¥785.53 Million +14.61%
2003-12-31 CN¥685.42 Million +750.83%
2002-12-31 CN¥80.56 Million +11.65%
2001-12-31 CN¥72.15 Million +10.61%
2000-12-31 CN¥65.23 Million --

Equity Component Analysis

This analysis shows how different components contribute to Zhejiang Huahai Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 555538085700.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥5.56 Billion 62.44%
Common Stock CN¥1.47 Billion 16.48%
Other Comprehensive Income CN¥244.47 Million 2.75%
Other Components CN¥1.63 Billion 18.33%
Total Equity CN¥8.90 Billion 100.00%

Zhejiang Huahai Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Zhejiang Huahai Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Danieli & C RSP
LSE:0N4I
 		$3.70 Billion
BILL Holdings, Inc.
SA:B2HI34
 		$3.70 Billion
Guaranty Trust Holding Co. PLC GDR
LSE:GTCO
 		$3.70 Billion
Zhende Medical Co Ltd
SHG:603301
 		$3.71 Billion
China Everbright Environment Group Limited
F:CNE
 		$3.70 Billion
Jiangsu Phoenix Publishing & Media Corp Ltd
SHG:601928
 		$3.70 Billion
Ninestar Corp
SHE:002180
 		$3.70 Billion
MANDARIN ORIENTAL DL-05
F:1C4
 		$3.70 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zhejiang Huahai Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 8,076,851,901 to 8,897,779,286, a change of 820,927,385 (10.2%).
  • Net income of 1,118,981,180 contributed positively to equity growth.
  • Dividend payments of 475,364,612 reduced retained earnings.
  • Share repurchases of 189,922,386 reduced equity.
  • Other comprehensive income increased equity by 44,271.
  • Other factors increased equity by 367,188,932.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥1.12 Billion +12.58%
Dividends Paid CN¥475.36 Million -5.34%
Share Repurchases CN¥189.92 Million -2.13%
Other Comprehensive Income CN¥44.27K +0.0%
Other Changes CN¥367.19 Million +4.13%
Total Change CN¥- 10.16%

Book Value vs Market Value Analysis

This analysis compares Zhejiang Huahai Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.76x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 290.95x to 2.76x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2000-12-31 CN¥0.06 CN¥16.88 x
2001-12-31 CN¥0.06 CN¥16.88 x
2002-12-31 CN¥0.07 CN¥16.88 x
2003-12-31 CN¥0.62 CN¥16.88 x
2004-12-31 CN¥0.71 CN¥16.88 x
2005-12-31 CN¥0.72 CN¥16.88 x
2006-12-31 CN¥0.70 CN¥16.88 x
2007-12-31 CN¥0.78 CN¥16.88 x
2008-12-31 CN¥0.89 CN¥16.88 x
2009-12-31 CN¥0.98 CN¥16.88 x
2010-12-31 CN¥1.04 CN¥16.88 x
2011-12-31 CN¥1.24 CN¥16.88 x
2012-12-31 CN¥1.59 CN¥16.88 x
2013-12-31 CN¥2.34 CN¥16.88 x
2014-12-31 CN¥2.40 CN¥16.88 x
2015-12-31 CN¥2.64 CN¥16.88 x
2016-12-31 CN¥3.25 CN¥16.88 x
2017-12-31 CN¥3.54 CN¥16.88 x
2018-12-31 CN¥3.10 CN¥16.88 x
2019-12-31 CN¥3.86 CN¥16.88 x
2020-12-31 CN¥4.48 CN¥16.88 x
2021-12-31 CN¥4.51 CN¥16.88 x
2022-12-31 CN¥5.17 CN¥16.88 x
2023-12-31 CN¥5.54 CN¥16.88 x
2024-12-31 CN¥6.12 CN¥16.88 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zhejiang Huahai Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 12.58%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 11.72%
  • • Asset Turnover: 0.47x
  • • Equity Multiplier: 2.28x
  • Recent ROE (12.58%) is below the historical average (17.62%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2000 53.28% 25.26% 0.76x 2.76x CN¥27.90 Million
2001 59.17% 23.96% 0.79x 3.11x CN¥35.41 Million
2002 62.23% 26.71% 0.75x 3.09x CN¥42.01 Million
2003 11.57% 26.16% 0.39x 1.13x CN¥10.76 Million
2004 15.19% 30.45% 0.44x 1.14x CN¥40.67 Million
2005 16.14% 30.46% 0.43x 1.22x CN¥49.02 Million
2006 12.69% 19.77% 0.51x 1.26x CN¥23.50 Million
2007 13.75% 18.67% 0.56x 1.32x CN¥35.98 Million
2008 13.79% 18.72% 0.53x 1.39x CN¥41.23 Million
2009 13.84% 17.78% 0.53x 1.46x CN¥45.79 Million
2010 7.22% 9.15% 0.50x 1.58x CN¥-36.11 Million
2011 14.19% 12.09% 0.70x 1.69x CN¥64.07 Million
2012 17.58% 16.93% 0.63x 1.66x CN¥147.04 Million
2013 11.94% 15.64% 0.51x 1.49x CN¥58.47 Million
2014 8.24% 10.27% 0.57x 1.40x CN¥-56.62 Million
2015 12.32% 12.64% 0.63x 1.54x CN¥83.36 Million
2016 11.43% 12.24% 0.61x 1.53x CN¥62.48 Million
2017 13.09% 12.78% 0.61x 1.69x CN¥151.02 Million
2018 2.64% 2.11% 0.49x 2.55x CN¥-299.46 Million
2019 10.15% 10.57% 0.50x 1.91x CN¥8.63 Million
2020 14.28% 14.34% 0.50x 1.99x CN¥278.52 Million
2021 7.43% 7.34% 0.43x 2.36x CN¥-168.35 Million
2022 15.47% 14.13% 0.46x 2.41x CN¥413.10 Million
2023 10.28% 10.00% 0.45x 2.30x CN¥22.78 Million
2024 12.58% 11.72% 0.47x 2.28x CN¥229.20 Million

Industry Comparison

This section compares Zhejiang Huahai Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $3,103,015,692
  • Average return on equity (ROE) among peers: 7.34%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Zhejiang Huahai Pharmaceutical Co Ltd (600521) CN¥9.60 Billion 53.28% 1.20x $3.70 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $1.97 Billion 4.04% 0.54x $1.45 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $536.15 Million 4.62% 0.32x $446.75 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.74 Billion 10.72% 0.24x $5.09 Billion
Livzon Pharmaceutical Group Inc (000513) $3.60 Billion 13.52% 0.82x $2.91 Billion
Wedge Industrial Co Ltd (000534) $643.84 Million 3.65% 1.07x $3.24 Billion
Yunnan Baiyao Group Co Ltd (000538) $427.59 Million 11.32% 0.85x $14.44 Billion
Hainan Haiyao Co Ltd (000566) $265.38 Million 9.41% 0.86x $1.05 Billion
Tus Pharmaceutical Group Co Ltd (000590) $322.78 Million 6.31% 0.77x $392.12 Million
Northeast Pharmaceutical Group Co Ltd (000597) $2.76 Billion 3.15% 2.10x $1.12 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $9.75 Billion 6.63% 0.12x $3.19 Billion

About Zhejiang Huahai Pharmaceutical Co Ltd

SHG:600521 China Drug Manufacturers - Specialty & Generic
Market Cap
$3.70 Billion
CN¥25.27 Billion CNY
Market Cap Rank
#4291 Global
#726 in China
Share Price
CN¥16.88
Change (1 day)
+3.62%
52-Week Range
CN¥14.13 - CN¥27.01
All Time High
CN¥43.62
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production and sales of generic drugs, biological drugs, and APIs in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and pol… Read more